AZGP1 activation by lenvatinib suppresses intrahepatic cholangiocarcinoma epithelial-mesenchymal transition through the TGF-β1/Smad3 pathway. The gene discussed is TGFB1; the disease is intrahepatic cholangiocarcinoma.